News NHS funding for five MS drugs under threat NICE calls for further discounts on beta-interferons and Copaxone
News Bill Gates enters dementia research with $50m donation Fund is challenging prevailing 'amyloid hypothesis'
News Biogen sees Spinraza slow down in Q3, bullish on Alzheimer's... Biogen has given investors a pleasant surprise with better-than-expected profits in Q3, but has puzzled analysts with a rapid slowdown for its new rare disease drug Spinraza.
News Ionis to file rare disease drug after GSK declines option Firm turns down options for inotersen and IONIS-FB-LRX.
News Biogen go quantum to speed up drug development Quantum computing algorithm could lead to new neurological disease drugs.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
